Why the study?
To analyze 90-day mortality in AF patients after stroke or severe bleeding and evaluate associations with antithrombotic treatment at the event.
Does preceding NOAC treatment compared to warfarin, antiplatelets, or no treatment improve 90-day mortality in AF patients suffering from ischaemic stroke, intracranial haemorrhage, or severe gastrointestinal bleed?
Population
6017 ischaemic stroke, 3006 intracranial haemorrhage, and 4291 severe GIB patients with known AF history
Comparison
Different antithrombotic treatments at the event including NOACs, warfarin, antiplatelets, or no treatment
Design
Database cohort study with propensity score-matched analyses
Follow-up
90-day
Authors
Loading...
NOAC pretreatment was associated with lower post-ICH mortality than warfarin; observational data leaves open causal inference and practice change.
Does preceding NOAC treatment compared to warfarin, antiplatelets, or no treatment improve 90-day mortality in AF patients suffering from ischaemic stroke, intracranial haemorrhage, or severe gastrointestinal bleed?
Preceding NOAC treatment is associated with lower 90-day mortality after intracranial hemorrhage compared to warfarin in patients with atrial fibrillation.
Komen et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: